CoChat
Sign Up
Cited by 51

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells

Rondón-Ortiz, Alejandro N., Lino Cardenas, Christian L., Martínez-Málaga, Jimena, Gonzales-Urday, Ana L., Gugnani, Kuljeet S., Böhlke, Mark, Maher, Timothy J., Pino-Figueroa, Alejandro J.·2017·Frontiers in Pharmacology
DOI 10.3389/fphar.2017.00772PMC PMC5696635
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2017.00772

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Ahmadian, 2013, PPARγ signaling and metabolism: the good, the bad and the future., Nat. Med., 19, 557, 10.1038/nm.3159 · DOI · Paper page
  2. Akhlaghi, 2017, Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with type 2 diabetes mellitus., Clin. Pharmacokinet., 56, 561, 10.1007/s40262-016-0472-6 · DOI
  3. Bown, 2011, Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1., Am. J. Hum. Genet., 89, 619, 10.1016/j.ajhg.2011.10.002 · DOI
  4. Cal, 2013, Aggregated low-density lipoprotein induces LRP1 stabilization through E3 ubiquitin ligase CHFR downregulation in human vascular smooth muscle cells., Arterioscler. Thromb. Vasc. Biol., 33, 369, 10.1161/ATVBAHA.112.300748 · DOI
  5. Cerquetti, 2011, Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells., Exp. Cell Res., 317, 1397, 10.1016/j.yexcr.2011.02.014 · DOI
  6. Dai, 2001, Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid., Pharmacogenetics, 11, 597, 10.1097/00008571-200110000-00006 · DOI
  7. Deane, 2004, LRP/Amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms., Neuron, 43, 333, 10.1016/j.neuron.2004.07.017 · DOI · Paper page
  8. Gan, 2014, Low-density lipoprotein receptor-related protein 1 (LRP1) regulates the stability and function of GluA1 α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor in neurons., PLOS ONE, 9, 10.1371/journal.pone.0113237 · DOI
  9. Gauthier, 2003, Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor γ., J. Biol. Chem., 278, 11945, 10.1074/jbc.M212989200 · DOI · Paper page
  10. Hauser, 2000, Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation., J. Biol. Chem., 275, 18527, 10.1074/jbc.M001297200 · DOI
  11. Ishikawa, 2004, A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin., J. Hum. Genet., 49, 582, 10.1007/s10038-004-0188-6 · DOI
  12. Jedrychowski, 2010, Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling., J. Biol. Chem., 285, 104, 10.1074/jbc.M109.040428 · DOI
  13. Kanai, 2014, KIF13B enhances the endocytosis of LRP1 by recruiting LRP1 to caveolae., J. Cell Biol., 204, 395, 10.1083/jcb.201309066 · DOI
  14. Kilroy, 2009, PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal., Obesity, 17, 665, 10.1038/oby.2008.616 · DOI
  15. Kim, 2004, Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells., Diabetes Metab. Res. Rev., S60, 10.2337/diabetes.53.2007.S60 · DOI
  16. Kim, 2014, The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression., Metabolism, 63, 112, 10.1016/j.metabol.2013.09.006 · DOI
  17. Kirchheiner, 2006, Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype., Clin. Pharmacol. Ther., 80, 657, 10.1016/j.clpt.2006.09.008 · DOI
  18. Korolchuk, 2009, Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates., Mol. Cell, 33, 517, 10.1016/j.molcel.2009.01.021 · DOI · Paper page
  19. Laatsch, 2009, Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance., Atherosclerosis, 204, 105, 10.1016/j.atherosclerosis.2008.07.046 · DOI
  20. Laatsch, 2012, Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E., PLOS ONE, 7, 10.1371/journal.pone.0029385 · DOI
  21. Lillis, 2008, LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies., Physiol. Rev., 88, 887, 10.1152/physrev.00033.2007 · DOI · Paper page
  22. Liu, 2015, Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain., J. Neurosci., 35, 5851, 10.1523/JNEUROSCI.5180-14.2015 · DOI
  23. Mao, 2017, Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARγ., Nat. Commun., 8, 10.1038/ncomms14960 · DOI
  24. Melman, 2002, Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway., Mol. Biol. Cell, 13, 3325, 10.1091/mbc.E02 · DOI
  25. Moon, Upregulation of hepatic LRP1 by rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia., J. Mol. Endocrinol., 49, 165, 10.1530/JME-12-0119 · DOI
  26. Moon, The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment., Int. J. Neuropsychopharmacol., 15, 135, 10.1017/S1461145711001611 · DOI
  27. Morrison, 2017, Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?, Sci. Rep., 7, 10.1038/s41598-017-02444-2 · DOI
  28. Niemi, 2003, Gemfibrozil considerably increases the plasma concentrations of rosiglitazone., Diabetologia, 46, 1319, 10.1007/s00125-003-1181-x · DOI
  29. Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes., N. Engl. J. Med., 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
  30. Pedersen, 2006, Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice., Exp. Neurol., 199, 265, 10.1016/j.expneurol.2006.01.018 · DOI
  31. Perrot, 2012, LRP-1-CD44, a new cell surface complex regulating tumor cell adhesion., Mol. Cell. Biol., 32, 3293, 10.1128/MCB.00228-12 · DOI
  32. Ramanathan, 2015, Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1., Front. Aging Neurosci., 7, 10.3389/fnagi.2015.00136 · DOI · Paper page
  33. Risner, 2006, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease., Pharmacogenomics J., 6, 246, 10.1038/sj.tpj.6500369 · DOI · Paper page
  34. Rubinsztein, 2009, In search of an “autophagomometer”., Autophagy, 5, 585, 10.4161/auto.5.5.8823 · DOI · Paper page
  35. Sagare, 2012, Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities., Pharmacol. Ther., 136, 94, 10.1016/j.pharmthera.2012.07.008 · DOI
  36. Sagare, 2011, From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid-β levels., J. Neurosci. Res., 89, 967, 10.1002/jnr.22670 · DOI
  37. Strickland, 2014, Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity., Arterioscler. Thromb. Vasc. Biol., 34, 487, 10.1161/ATVBAHA.113.301924 · DOI
  38. Tamaki, 2006, Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver., Pharm. Res., 23, 1407, 10.1007/s11095-006-0208-7 · DOI · Paper page
  39. Tornio, 2012, Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications., Trends Pharmacol. Sci., 33, 312, 10.1016/j.tips.2012.03.001 · DOI
  40. Van Gool, 2015, The matricellular receptor LRP1 forms an interface for signaling and endocytosis in modulation of the extracellular tumor environment., Front. Pharmacol., 6, 10.3389/fphar.2015.00271 · DOI
  41. Vara, 2013, Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma., Cell Death Dis., 4, 10.1038/cddis.2013.141 · DOI
  42. Vilchez, 2014, The role of protein clearance mechanisms in organismal ageing and age-related diseases., Nat. Commun., 5, 10.1038/ncomms6659 · DOI
  43. Wild, 2012, Low density lipoprotein receptor related protein 1 and abdominal aortic aneurysms., Eur. J. Vasc. Endovasc. Surg., 44, 127, 10.1016/j.ejvs.2012.05.009 · DOI
  44. Zhou, 2009, PPARγ activation induces autophagy in breast cancer cells., Int. J. Biochem. Cell Biol., 41, 2334, 10.1016/j.biocel.2009.06.007 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rondón-Ortiz, A. N., Lino Cardenas, C. L., Martínez-Málaga, J., Gonzales-Urday, A. L., Gugnani, K. S., Böhlke, M., Maher, T. J., & Pino-Figueroa, A. J.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2017-11-14
Volume
8
ISSN
1663-9812
DOI
10.3389/fphar.2017.00772
PMC
PMC5696635
Cited by
51
References
6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review